Zenas BioPharma appoints Orlando Oliveira as chief commercial officer

Mr. Oliveira is a seasoned biopharmaceutical executive with nearly 25 years of commercial experience, building high-performing teams and bringing multiple successful pharmaceutical products to market.

WALTHAM, Mass., July 1, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies, today announced the appointment of Orlando Oliveira as its Chief Commercial Officer. With a career spanning nearly 25 years, Mr. Oliveira brings extensive experience in building high-performing global commercial teams, driving revenue growth and fostering strategic partnerships across the biotechnology and pharmaceutical industries.

“As we continue to pursue multiple mid- and late-stage clinical development programs, we are pleased to welcome Orlando to the Zenas leadership team,” said Joe Farmer, president and chief operating officer. “His knowledge and experience in building and leading high-performing commercial teams will be instrumental in establishing the oxelimab franchise and achieving our goal of making oxelimab available to patients around the world. We will benefit greatly from Orlando’s extensive commercial expertise and leadership as Zenas evolves into an integrated development and commercial biopharmaceutical company.”

“I am eager to join the experienced leadership team that has built Zenas with a mission to deliver transformative immunology-based therapies to patients in need,” said Mr. Oliveira. “I look forward to working with this team to further develop and execute the strategy and plans for the ultimate commercialization of obexelimab and to establish Zenas as a leading global immunology-based development and commercialization company.”

Prior to joining Zenas, Mr. Oliveira served as Senior Vice President and Chief International Officer at Mirati Therapeutics (acquired by Bristol Meyers Squibb), where he helped lead and build the company’s international foundation and led multiple oncology launches, including the European Medicines Agency approval of KRAZATI^®. Previously, he served as Senior Vice President and General Manager, International, at Agios Pharmaceuticals (an oncology company acquired by Servier) and in the same capacity at TESARO (acquired by GlaxoSmithKline). Prior to that, he served as Vice President, European and Intercontinental Operations, at Cubist Pharmaceuticals (acquired by Merck). Mr. Oliveira also held numerous positions of increasing responsibility at Amgen for over a decade. Mr. Oliveira currently serves as a member of the Board of Directors of OncoInvent AS, a privately held clinical stage radiopharmaceutical company. He holds a degree in Pharmacy and postgraduate degrees in Drug Law and Pharmacy from the University of Coimbra, Portugal.

The story continues

About Zenas BioPharma

Zenas BioPharma is a global clinical-stage biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies for patients in need. With clinical development capabilities and operations around the world, Zenas is advancing a portfolio of potentially differentiated autoimmune therapies in areas of high unmet medical need. Zenas’ experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of people struggling with autoimmune diseases. For more information about Zenas BioPharma, visit www.zenasbio.com and follow us on X at @ZenasBioPharma and on LinkedIn.

Contact for investors and media: :
Argot Partners
[email protected]